

ONE HUNDRED SIXTH LEGISLATURE - SECOND SESSION - 2020
COMMITTEE STATEMENT
LB1221

Hearing Date: Friday February 21, 2020
Committee On: Judiciary
Introducer: Wayne
One Liner: Change controlled substance schedules for certain federally approved drugs containing derivatives of cannabis

Roll Call Vote - Final Committee Action:
Advanced to General File with amendment(s)

Vote Results:
Aye: 8 Senators Brandt, Chambers, DeBoer, Lathrop, Morfeld, Pansing Brooks, Slama, Wayne
Nay:
Absent:
Present Not Voting:

Oral Testimony:

Proponents:
Senator Justin Wayne
Jan Dahlke Anderson

Representing:
Introducer
Greenwich Biosciences

Opponents:
John Cartier
Bill Hawkins

Representing:
self
Nebraska Hemp Company

Neutral:

Representing:

Summary of purpose and/or changes:

Section 1 would amend Sec. 28-401, which contains the definitions for the Uniform Controlled Substances Act. Concentrated cannabis would be excluded from the definition of marijuana and THC in a product approved by the FDA would also be excluded from the definition of marijuana. A product approved by the FDA that includes CBD or THC would be excluded from the definition of "hashish or concentrated cannabis". These products would also be removed from the definition of "cannabinoid receptor agonist".

Section 2 would amend Sec. 28-405 to remove THC and CBD in products approved by the FDA from the schedule of controlled substances.

Explanation of amendments:

Committee amendment AM2614 removes Epidiolex and nabiximols from various provisions in the state's Uniform Controlled Substances Act as these drugs have been approved by the Federal Food and Drug Administration and removed from federal controlled substances provisions.

Steve Lathrop, Chairperson